- Trials with a EudraCT protocol (824)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
824 result(s) found for: skin cancer.
Displaying page 1 of 42.
EudraCT Number: 2014-002175-28 | Sponsor Protocol Number: DACOMINT14 | Start Date*: 2014-08-04 | |||||||||||
Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori | |||||||||||||
Full Title: Efficacy and safety of single agent pan-HER inhibitor Dacomitinib in the treatment of locally advanced unresectable or metastatic squamous cell cancer of the skin or with clinical contraindication... | |||||||||||||
Medical condition: locally advanced unresectable or metastatic squamous cell cancer of the skin or with clinical contraindication to surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011455-51 | Sponsor Protocol Number: AA0906 | Start Date*: 2009-05-29 | |||||||||||
Sponsor Name:Department of Oncology, University Hospital Herlev | |||||||||||||
Full Title: Palliative treatment of ulcerated cutaneous metastases: Randomised trial between electrochemotherapy and radiotherapy | |||||||||||||
Medical condition: Ulcerated cutaneous metastases from solid tumor cancers is a particularly difficult problem with painful skin ulceration, maladorous discharge and bleeding. The intention of this study is to invest... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003495-31 | Sponsor Protocol Number: CCLL442X2201 | Start Date*: 2017-12-14 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, Investigator-and patient-blind, placebo-controlled, parallel group first in human and proof of concept study to evaluate the safety, tolerability, and efficacy of CLL442 in patients w... | |||||||||||||
Medical condition: Cutaneous Squamous Cell Carcinoma in situ (SCCis) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001384-23 | Sponsor Protocol Number: 65512-SAFESTOP | Start Date*: 2018-11-08 | |||||||||||
Sponsor Name:Erasmus Medical Center | |||||||||||||
Full Title: Safe Stop Trial: observational study of the STOP & GO strategy of PD-1 blockade in advanced melanoma patients upon achieving a complete or partial response | |||||||||||||
Medical condition: malignant and not otherwise specified skin neoplasms | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006863-35 | Sponsor Protocol Number: 314759 | Start Date*: 2013-10-01 | |||||||||||||||||||||
Sponsor Name:Bispebjerg Hospital | |||||||||||||||||||||||
Full Title: Prophylactic photodynamic therapy for organ transplant patients – a randomised, intra-individual trial with blinded outcome evaluation. | |||||||||||||||||||||||
Medical condition: Development of actinic keratoses and skin cancer in kidney transplant patients - a randomised, intra-individual trial with blinded outcome evaluation. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003765-10 | Sponsor Protocol Number: I-Tackle | Start Date*: 2018-07-10 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: Immunotherapy Followed By EGFR Inhibitor In Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin: Tackling Primary And Secondary Resistance | |||||||||||||
Medical condition: Patient with Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003531-30 | Sponsor Protocol Number: WIDECT | Start Date*: 2020-04-03 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | |||||||||||||
Full Title: Electrochemotherapy versus narrow excision margins for high-risk, primary cutaneous melanoma | |||||||||||||
Medical condition: primary cutaneous melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005704-17 | Sponsor Protocol Number: AA1232 | Start Date*: 2013-03-27 | |||||||||||
Sponsor Name:Julie Gehl | |||||||||||||
Full Title: Calcium electroporation for the treatment of cutaneous metastases. | |||||||||||||
Medical condition: Patients suffering from advanced cancer with cutaneous metastases. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000427-17 | Sponsor Protocol Number: CY503C1 | Start Date*: 2007-10-26 | |||||||||||
Sponsor Name:CYTAVIS BioPharma GmbH | |||||||||||||
Full Title: A phase II multicenter study to test progression- free and overall survival of CY-503 in the treatment of patients with unresectable stage IV metastatic melanoma after antineoplastic treatment failure | |||||||||||||
Medical condition: unresectable progressive metastatic melanoma stage IV after antineoplastic treatmet failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022938-85 | Sponsor Protocol Number: AIO-LQ-0110 | Start Date*: 2011-04-27 |
Sponsor Name:AIO-Studien-gGmbH | ||
Full Title: Comparison of two preemptive treatment strategies of panitumumab mediated skin toxicity and assessment of quality of life in patients with Ras-wildtype colorectal cancer | ||
Medical condition: Panitumumab-mediated Skin toxicity in palliative treatment of Metastatic colorectal cancer with panitumumab | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001708-12 | Sponsor Protocol Number: 4518000 | Start Date*: 2018-12-19 | |||||||||||
Sponsor Name:Alcedis GmbH | |||||||||||||
Full Title: A single arm phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in combination with cetuximab in subjects with unresectable stage III or stage IV cu... | |||||||||||||
Medical condition: Unresectable stage III or stage IV cutaneous squamous cell carcinoma (cSCC) | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006087-49 | Sponsor Protocol Number: MEK115306 | Start Date*: 2012-04-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subjec... | |||||||||||||
Medical condition: Cutaneous melanoma - aggressive form of skin cancers. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) ES (Completed) GB (Completed) NL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006372-17 | Sponsor Protocol Number: Field-Cancerization | Start Date*: 2022-02-15 | |||||||||||
Sponsor Name:Muehlenkreiskliniken AoeR | |||||||||||||
Full Title: Evaluation of clinical and immunological effects of PD-1 inhibition on actinic keratoses in patients with advanced or metastatic cutaneous squamous cell carcinoma in combination with a pronounced f... | |||||||||||||
Medical condition: advanced or metastatic cutaneous squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018638-29 | Sponsor Protocol Number: LUC10-001 | Start Date*: 2012-04-23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Centre du Cancer des Cliniques Universitaires Saint-Luc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase I/II study of peptide vaccination associated with GM-CT-01, a galactomannan oligomer that inhibits galestin-3, in patients with advanced metastatic melanoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Metastatic melanoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-001469-34 | Sponsor Protocol Number: NEO-CESQ | Start Date*: 2020-10-20 | |||||||||||
Sponsor Name:FONDAZIONE MELANOMA ONLUS | |||||||||||||
Full Title: A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in high risk, surgically resectable, stage III Cutaneaous Squamous Cell Carcinoma | |||||||||||||
Medical condition: high risk, surgically resectable, stage III Cutaneous Squamous Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005332-30 | Sponsor Protocol Number: ACT16845 | Start Date*: 2021-09-27 | ||||||||||||||||
Sponsor Name:SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT | ||||||||||||||||||
Full Title: A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR- 707) combined with cemiplimab for the treatment of participants with adva... | ||||||||||||||||||
Medical condition: Advanced unresectable or metastatic skin cancers | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000092-33 | Sponsor Protocol Number: PDTA02_24.05.2013 | Start Date*: 2013-10-23 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.Klinik.f.Dermatologie | |||||||||||||
Full Title: Enhanced efficacy of photodynamic therapy in combination with 5% imiquimod -a randomised, prospective, observer-blinded study in patients with non melanoma skin cancer | |||||||||||||
Medical condition: non melanoma skin cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004387-18 | Sponsor Protocol Number: CO39722 | Start Date*: 2018-01-09 | |||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED AD... | |||||||||||||
Medical condition: Metastatic BRAFV600 wild-type melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) BE (Completed) HU (Completed) PL (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) GR (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006344-19 | Sponsor Protocol Number: D1532C00006 | Start Date*: 2009-09-03 | |||||||||||||||||||||||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||||||||||||||||||||||
Full Title: A Phase II, Double-Blind, Randomised Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Dacarbazine Compared with Dacarbazine Alone in First Line Patients with BRAF Mutation ... | |||||||||||||||||||||||||||||||||
Medical condition: BRAF mutation positive advanced cutaneous and unknown primary melanoma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) CZ (Completed) FR (Completed) SE (Completed) HU (Completed) ES (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002276-13 | Sponsor Protocol Number: CA209-7DL | Start Date*: 2020-04-27 | |||||||||||
Sponsor Name:University Hospital Essen, Department of Dermatology | |||||||||||||
Full Title: Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratification | |||||||||||||
Medical condition: Stage II melanoma arising from a primary cutaneous site after surgery therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
